泰励生物科技
  • EN
  • 中文

Home

News

Company News
Industry News

About Us

Company Profile
Vision & Mission
Our Values
Leadership Team
R&D Strategy
Focusing Fields
Investors

Collaborations

Join Us

Contact Us

Where you are now: News > Company News

News

  • Company News
  • Industry News
  • Tyligand Bioscience and Context Therapeutics Sign Strategic Development Agreement for Onapristone ER

    2020-03-13

    Tyligand Bioscience and Phildelphia based biotech Context Therapeutics announced the signing of collaboration agreements for the development, manufacturing, registration and future commercialization of onapristone extended release (ER).

    查看详情
  • Home
  • Site Map
  • Terms of use
  • Privacy Policy
  • Contact Us
© 2019 Tyligand Bioscience (Shanghai) Limited. All Rights Reserved.
中文 | EN